Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company is focusing on the growth API business, which is showing healthy expansion and good margin profiles. The company is focusing on building its growth API business, which is delivering healthy gross margins (~56%) and EBITDA (~25%), higher than the industry average.
From Solara Active Pharma Sciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company is focusing on the growth API business, which is showing healthy expansion and good margin profiles.
- Current capacity utilization in the growth API segment is about 70%.
- The Vizag facility is being revamped into a multipurpose and high-potent API plant to support future growth.
- Launch of new APIs, including one associated with OneSource, is expected by FY '27, indicating upcoming revenue opportunities.
- The company is cautious about giving specific guidance for API growth until resolution and strategic decisions regarding the ibuprofen business are finalized.
- Overall revenue growth is expected to be driven primarily by the non-ibuprofen, high-margin API portfolio.
2 more points from Solara Active Pharma Sciences Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Solara Active Pharma Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Significant investments are underway to convert the Vizag facility from a single-product ibuprofen plant to a multipurpose plant and a high-potent API plant.
- Investments include converting one of the blocks at Vizag for multipurpose use and another for high-potent API production.
- R&D capabilities are being revived and enhanced to support the new operational focus at Vizag, with new talent onboarded.
- Planned capital infusion will focus on building the growth API business, with a clear intent to ramp up Vizag back into commercial production within the next 5 to 6 months.
2 more points from Solara Active Pharma Sciences Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Solara Active Pharma Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Solara Active Pharma Sciences Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Solara Active Pharma Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹417 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Solara Active's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Arthneeti Pro · Annual
Solara Active Pharma Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Solara Active Pharma Sciences Ltd Q3 FY26 results?
The company is focusing on the growth API business, which is showing healthy expansion and good margin profiles. The company is focusing on building its growth API business, which is delivering healthy gross margins (~56%) and EBITDA (~25%), higher than the industry average.
What is Solara Active Pharma Sciences Ltd share price analysis?
Solara Active Pharma Sciences Ltd currently shows a neutral. The stock trades at a P/E of 573.4 with a market cap of ₹2,448 Cr. Investors should review the full earnings analysis for detailed insights.
Is Solara Active Pharma Sciences Ltd planning capital expenditure?
Significant investments are underway to convert the Vizag facility from a single-product ibuprofen plant to a multipurpose plant and a high-potent API plant.
Keep Solara Active Pharma Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.